Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

281.41 -9.68 (-3.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
52 53 Next >
The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, Amgen
All eyes are on tirzepatide, but its next-generation weight-loss shot could be even better. 
Via Investor's Business Daily
Pinterest To Rally Around 23%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
Cramers Says These 3 Big Deals Aided Monday's Market Rally: 'When Companies Start Buying Each Other At A Big Premium...'
Prominent market commentator Jim Cramer said three corporate deals announced on Monday aided the rally seen at the beginning of the week,  
Via Benzinga
Nasdaq, S&P 500 Futures Soar Amid Optimistic Expectations Concerning Nov. Inflation: Oracle, Tesla, Pinterest Among Early Movers
The index futures point to a modestly higher opening for the market on Tuesday, although the November consumer price inflation due ahead of the open could sway sentiment either way depending on how the... 
Via Benzinga
Tesla, Apple, Rivian, Horizon, Paypal: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1% higher on Monday after last week’s subdued performance. 
Via Benzinga
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
FDA action on its KRAS-blocking drug could help recently downtrodden Mirati. 
Via Investor's Business Daily
Here's Where Amgen's Loan To Acquire Horizon Therapeutics For $28B Ranks Among M&A Deals In 2022
Amgen Inc's (NASDAQ: AMGN) deal to acquire Horizon Therapeutics (NASDAQ: HZNP) requires a sizable loan that ranks among the biggest debt commitments for 
Via Benzinga
Why Horizon Therapeutics Stock Is Soaring Today
Amgen's planned acquisition of Horizon could close in the first half of next year. 
Via The Motley Fool
What's Going On With Amgen Stock Today?
Amgen Inc (NASDAQ: AMGN) shares are trading lower Monday after the company announced it will acquire Horizon Therapeutics (NASDAQ: HZNP) 
Via Benzinga
Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal
HZNP stock is up on news that Horizon Therapeutics is being bought by Amgen in a friendly deal that's positive for both companies. 
Via InvestorPlace
Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal
The deal comes a day after Sanofi dropped out of the bidding process. 
Via Investor's Business Daily
These 2 Nasdaq Stocks Are Soaring on Merger News
Find out which companies are attracting interest from prospective buyers. 
Via The Motley Fool
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
Via Benzinga
Could Amgen's Heart Disease Candidate Generate Billions in Sales?
Amgen recently shared positive clinical trial results for a heart disease drug candidate. 
Via The Motley Fool
How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again
Eli Lilly is expected to make a key decision for a next-generation obesity drug. 
Via Investor's Business Daily
Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days
The company is still planning a Phase 3 study in non-small cell lung cancer. 
Via Investor's Business Daily
Here's What We Know So Far About Amgen's Obesity Drug As It Trails Novo Nordisk, Eli Lilly
Amgen is trying to play catch-up with Novo Nordisk and Eli Lilly. 
Via Investor's Business Daily
This Monster Dividend Stock Isn't Done Growing
Is another deal on the way for Johnson & Johnson? 
Via The Motley Fool
Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
Via Benzinga
Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up
The combination with Keytruda appears safe, but effectiveness questions persist. 
Via Investor's Business Daily
Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy
Via Benzinga
Is AbbVie Stock a Buy Now?
The pharmaceutical company prepared well as Humira approaches its patent cliff next year. 
Via The Motley Fool
Amgen Unusual Options Activity For December 05
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 13 strange trades. 
Via Benzinga
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi
There are now two companies in the ring for a Horizon takeover. 
Via Investor's Business Daily
7 Christmas Stocks to Buy for Happy Holidays
This year took a toll on a lot of portfolios, leaving many investors feeling more like a Grinch than looking for Christmas stocks to buy. 
Via InvestorPlace
FTX Collapse: Lessons for Investors
Plus a look at "the dumbest index." 
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
If Sanofi Opted For Takeover Of Horizon Therapeutics, It Would Be In Cash
Via Benzinga
Is Amgen Stock a Buy for Income Investors?
Amgen's dividend yield is materially higher than the S&P 500 index's yield. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.